NEW DELHI (February 25, 2026) — The Central Drugs Standard Control Organization (CDSCO), India’s apex drug regulatory body, has overhauled its protocols for granting testing permissions to significantly reduce the time required for new drug approvals. Under the newly modified norms, pharmaceutical companies can now begin laboratory testing immediately upon filing an application, bypassing the previously mandatory waiting period for detailed regulatory scrutiny.
Shift from Scrutiny to Instant Issuance
Previously, the CDSCO conducted a comprehensive examination of the detailed specifications and protocols—including Critical Quality Attributes (CQAs), product development reports, and forced degradation studies—before issuing a No Objection Certificate (NOC) for testing. This pre-approval phase often added several weeks or months to the development timeline.
In an official circular dated February 23, 2026, the CDSCO clarified that the NOC for testing drug samples at designated national laboratories shall be issued “immediately upon receipt of applications” in the concerned division. This “deemed approval” approach shifts the focus to faster file movement while retaining technical scrutiny for later stages of the approval process.
Designated National Testing Laboratories
The directive applies to testing conducted at India’s premier designated laboratories:
- IPC, Ghaziabad: Indian Pharmacopoeia Commission.
- CDTL, Mumbai: Central Drugs Testing Laboratory.
- CRI, Kasauli: Central Research Institute (Central Drugs Laboratory).
- NIB, Noida: National Institute of Biologicals.
Key Requirements for Applicants
While the NOC is now issued instantly, the CDSCO has introduced stricter upfront documentation requirements to maintain quality standards:
- Finalised Specifications: Applicants must submit finalised regulatory specifications based on prevailing Pharmacopoeia standards and Product-Specific Quality Management Systems (QMS) at the time of filing.
- Mandatory Re-testing: If specifications are revised or updated following later CDSCO review or comments, a fresh NOC must be obtained for re-testing at the designated laboratory.
- Effective Date: The new system is scheduled to come into effect from June 1, 2026.
Broader Regulatory Context
This move is part of a series of recent reforms aimed at enhancing the “Ease of Doing Business” in India’s pharmaceutical sector. Other recent updates in 2026 include:
- NDCT Amendment Rules 2026: Reduction in regulatory review timelines from 90 days to 45 days.
- Prior Intimation Pathway: Allowing manufacturers of lower-risk drugs to commence certain activities based on a simple online intimation rather than waiting for formal permission.
- Scientific Cadre Expansion: The CDSCO is in the process of creating a 1,500-member scientific cadre, including global industry experts, to bring Indian approval timelines at par with—or better than—the US FDA.
Sources
- Central Drugs Standard Control Organization (CDSCO): Official Circular No. DCG(I)/MISC/2026 (4) (February 23, 2026)
- Press Trust of India (PTI): “CDSCO modifies norms for testing permissions to speed up drug approvals” (February 25, 2026)
- Business Standard: “CDSCO allows immediate lab testing of drugs to speed up approvals” (February 26, 2026)
- Medical Dialogues: “Immediate NOC from June 1: CDSCO Revises Drug Testing Norms” (February 27, 2026)
Leave a Reply